基于肠道菌群探讨高血压的机制与研究进展  

Research progress and mechanism exploration of hypertension based on intestinal flora

作　　者：于婷婷 罗磊 詹磊[3] 蔡岳 杨帆[2] YU Tingting;LUO Lei;ZHAN Lei;CAI Yue;YANG Fan(The First Clinical College,Hubei University of Chinese Medicine,Hubei Province,Wuhan430061,China;Health Management Center,Hubei Provincial Hospital of Traditional Chinese Medicine,Hubei Province,Wuhan430074,China;Department of Hepatology,Hubei Provincial Hospital of Traditional Chinese Medicine,Hubei Province,Wuhan430061,China)

机构地区：[1]湖北中医药大学第一临床学院,湖北武汉430061 [2]湖北省中医院健康管理中心,湖北武汉430074 [3]湖北省中医院肝病科,湖北武汉430061

出　　处：《中国医药导报》2025年第1期83-87,共5页China Medical Herald

摘　　要：高血压是重大公共卫生问题,但机制尚未明确。目前越来越多的证据显示,肠道菌群在高血压的发生、发展和发病机制中起重要作用。肠道菌群可通过代谢产物及影响免疫系统和肠屏障等升高血压。微生物组考虑整合到临床前研究中至关重要,通过粪便微生物群移植改善肠道菌群,可降低血压。因此,深入研究肠道菌群在高血压中的作用,有助于为高血压的预防和治疗提供更多有意义的策略。Hypertension is a major public health issue,but the mechanism is not yet clear.Currently,more and more evidences show that intestinal flora plays an important role in the occurrence,development,and pathogenesis of hypertension.Intestinal flora can promote blood pressure elevation through metabolic products,affecting immune system and intestinal barrier.Integrating microbiome considerations into preclinical studies is crucial,improving intestinal flora through fecal microbiota transplantation can lower blood pressure.Therefore,in-depth research on the role of intestinal flora in hypertension can help provide more meaningful strategies for the prevention and treatment of hypertension.

关 键 词：高血压 发病机制 肠道菌群 治疗策略 

分 类 号：R544.1[医药卫生—心血管疾病]